speb/financial-data huggingface dataset:
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Pretax Income: 861559000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 657348000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 187469000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Special Income Charges: -32754000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -8559328.58
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Tax Provision: 225144000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.26
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Total Expenses: 1975325000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items: -32754000.00
CONCORDBIO.NS income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -32754000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — +Operating Expense: 4815369000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — +Operating Expense: 1412771000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — +Total Revenue: 10463581000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — +Total Revenue: 3260796000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Accounts Payable: 1019094000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 1019094000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Accounts Receivable: 4601971000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 4601971000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Accumulated Depreciation: -3601094000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -3601094000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Additional Paid In Capital: 819710000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 819710000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -59343000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -59343000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Amortization: 3514000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Amortization Cash Flow: 3514000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Available For Sale Securities: 849372000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Available For Sale Securities: 849372000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Basic Average Shares: 104953310.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Basic EPS: 8.46
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Beginning Cash Position: 9045000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Buildings And Improvements: 3753503000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Buildings And Improvements: 3753503000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Capital Expenditure: -951511000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Capital Lease Obligations: 23156000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 23156000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Capital Stock: 104616000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Capital Stock: 104616000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Cash And Cash Equivalents: 121860000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 121860000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 4066253000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 4066253000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Cash Dividends Paid: -1119393000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Change In Inventory: -866889000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Change In Other Current Assets: 57515000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Change In Other Current Liabilities: 1098000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Change In Payable: -85198000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Change In Receivables: 704529000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Change In Working Capital: -139228000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Changes In Cash: 112815000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Common Stock: 104616000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Common Stock: 104616000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Common Stock Dividend Paid: -1119393000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Common Stock Equity: 20170613000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 20170613000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Construction In Progress: 877709000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Construction In Progress: 877709000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Cost Of Revenue: 2599855000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 858149000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Current Assets: 12501118000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Current Assets: 12501118000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Current Capital Lease Obligation: 8822000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 8822000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Current Debt: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Current Debt: 0.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Current Debt And Capital Lease Obligation: 8822000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 8822000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Current Liabilities: 1690771000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 1690771000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Current Provisions: 112343000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Current Provisions: 112343000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Depreciation: 741072000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Depreciation And Amortization: 744586000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Depreciation And Amortization In Income Statement: 744586000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 195439000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Depreciation Income Statement: 741072000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Depreciation Income Statement: 195439000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 104953310.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Diluted EPS: 8.46
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Diluted NI Availto Com Stockholders: 2609059000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: 887905000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Dividends Payable: 581000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Dividends Payable: 581000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — EBIT: 3449292000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — EBIT: 1141594000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — EBITDA: 4193878000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — EBITDA: 1337033000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — End Cash Position: 121860000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Financing Cash Flow: -1128762000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Finished Goods: 319155000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Finished Goods: 319155000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Free Cash Flow: 1717302000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Gain Loss On Investment Securities: -211277000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Gain Loss On Sale Of PPE: -130000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — General And Administrative Expense: 131908000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Goodwill: 3963000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Goodwill: 3963000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Goodwill And Other Intangible Assets: 18211000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 18211000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Gross Accounts Receivable: 4661314000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 4661314000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Gross PPE: 12357783000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Gross PPE: 12357783000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Gross Profit: 7863726000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Gross Profit: 2402647000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Hedging Assets Current: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Hedging Assets Current: 0.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Interest Expense: 2820000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Interest Expense: 840000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Interest Expense Non Operating: 2820000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 840000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Interest Income: 24629000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Interest Income Non Operating: 24629000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Interest Paid Cff: -2832000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Interest Received Cfi: 23977000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Inventory: 3263561000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Inventory: 3263561000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Invested Capital: 20170613000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Invested Capital: 20170613000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Investing Cash Flow: -1427236000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Investmentin Financial Assets: 849372000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Investmentin Financial Assets: 849372000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Investmentsin Joint Venturesat Cost: 36457000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Investmentsin Joint Venturesat Cost: 36457000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Land And Improvements: 629929000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Land And Improvements: 629929000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Long Term Capital Lease Obligation: 14334000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 14334000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 14334000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 14334000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Long Term Debt Payments: -3811000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Long Term Equity Investment: 36457000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 36457000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Long Term Provisions: 37197000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Long Term Provisions: 37197000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Machinery Furniture Equipment: 6371805000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 6371805000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Minority Interest: -19233000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Minority Interest: -19233000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Minority Interests: 16768000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Minority Interests: 3235000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -109481000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Net Income: 2609059000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Net Income: 887905000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Net Income Common Stockholders: 2609059000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: 887905000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Net Income Continuous Operations: 2592291000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: 884669000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 2609059000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: 887905000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 2609059000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: 887905000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Net Income From Continuing Operations: 3446472000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Net Income Including Noncontrolling Interests: 2592291000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: 884669000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Net Interest Income: 16395000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Net Interest Income: -840000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Net Investment Purchase And Sale: -644033000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Net Issuance Payments Of Debt: -3811000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Net Long Term Debt Issuance: -3811000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Net Non Operating Interest Income Expense: 16395000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -840000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Net Other Investing Changes: 143328000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Net PPE: 8756689000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Net PPE: 8756689000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Net PPE Purchase And Sale: -950508000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Net Tangible Assets: 20152402000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 20152402000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Assets: 29366000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Assets: 29366000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Non Current Deferred Taxes Liabilities: 453589000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Non Current Deferred Taxes Liabilities: 453589000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 37197000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 37197000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Non Current Prepaid Assets: 104106000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Non Current Prepaid Assets: 104106000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Normalized EBITDA: 4015225000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Normalized EBITDA: 1337033000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Normalized Income: 2475051384.70
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Normalized Income: 887905000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Operating Cash Flow: 2668813000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Operating Income: 3048357000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Operating Income: 989876000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Operating Revenue: 10463581000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Operating Revenue: 3260796000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Ordinary Shares Number: 104616204.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 104616204.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Other Current Assets: -1000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Other Current Assets: -1000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Other Current Liabilities: 123379000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 123379000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Other Equity Interest: 20065997000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Other Equity Interest: 20065997000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Other Intangible Assets: 14248000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 14248000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Other Inventories: 12357000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Other Inventories: 12357000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Other Non Cash Items: -21797000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Other Non Current Assets: 159152000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Other Non Current Assets: 159152000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Other Non Operating Income Expenses: 13771000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Other Non Operating Income Expenses: 153494000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Other Operating Expenses: 1907478000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 739620000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Other Payable: 434167000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Other Payable: 434167000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Other Properties: 724837000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Other Properties: 724837000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Other Receivables: 50842000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Other Receivables: 50842000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Other Short Term Investments: 4066253000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Other Short Term Investments: 4066253000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Other Special Charges: 32624000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Otherunder Preferred Stock Dividend: 0.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Payables: 1453934000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Payables: 1453934000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Prepaid Assets: 215256000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 215256000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Pretax Income: 3446472000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Pretax Income: 1140754000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Properties: 0.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Provisionand Write Offof Assets: -7174000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Purchase Of Investment: -9468121000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Purchase Of PPE: -951511000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Raw Materials: 989727000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Raw Materials: 989727000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Reconciled Cost Of Revenue: 2599855000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 858149000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Reconciled Depreciation: 744586000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 195439000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Rent And Landing Fees: 89156000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Rent Expense Supplemental: 89156000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Repayment Of Debt: -3811000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Restricted Cash: 253592000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Restricted Cash: 253592000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Retained Earnings: 18958117000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Retained Earnings: 18958117000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Sale Of Investment: 8824088000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Sale Of PPE: 1003000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Selling And Marketing Expense: 334760000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Selling General And Administration: 466668000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Share Issued: 104616204.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Share Issued: 104616204.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Special Income Charges: -32624000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Special Income Charges: 0.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Stockholders Equity: 20170613000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 20170613000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Tangible Book Value: 20152402000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 20152402000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Tax Effect Of Unusual Items: 44645384.70
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Tax Provision: 854181000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Tax Provision: 256085000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Tax Rate For Calcs: 0.25
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.22
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Taxes Receivable: 49644000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 49644000.00
CONCORDBIO.NS cash_flow (annual, 2026-03-31) — Taxes Refund Paid: -1004066000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Total Assets: 22347271000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Total Assets: 22347271000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Total Capitalization: 20170613000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 20170613000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Total Debt: 23156000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Total Debt: 23156000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Total Equity Gross Minority Interest: 20151380000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 20151380000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Total Expenses: 7415224000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Total Expenses: 2270920000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Total Liabilities Net Minority Interest: 2195891000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 2195891000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Total Non Current Assets: 9846153000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 9846153000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 505120000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 505120000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Total Other Finance Cost: 5414000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Total Tax Payable: 92000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Total Tax Payable: 92000.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Total Unusual Items: 178653000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items: 0.00
CONCORDBIO.NS income_statement (annual, 2026-03-31) — Total Unusual Items Excluding Goodwill: 178653000.00
CONCORDBIO.NS income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 0.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Work In Process: 1942322000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Work In Process: 1942322000.00
CONCORDBIO.NS balance_sheet (annual, 2026-03-31) — Working Capital: 10810347000.00
CONCORDBIO.NS balance_sheet (quarterly, 2026-03-31) — Working Capital: 10810347000.00
CONE.V cash_flow (annual, 2021-07-31) — Capital Expenditure Reported: -8000.00
CONE.V balance_sheet (annual, 2021-07-31) — Current Accrued Expenses: 18625.00
CONE.V balance_sheet (annual, 2021-07-31) — Current Provisions: 18000.00
CONE.V income_statement (annual, 2021-07-31) — Gain On Sale Of Security: 144.00
CONE.V income_statement (annual, 2021-07-31) — Interest Expense: 13604.00
CONE.V income_statement (annual, 2021-07-31) — Interest Expense Non Operating: 13604.00
CONE.V balance_sheet (annual, 2021-07-31) — Line Of Credit: 0.00
CONE.V cash_flow (annual, 2021-07-31) — Long Term Debt Payments: -15960.00
CONE.V income_statement (annual, 2021-07-31) — Net Interest Income: -13604.00
CONE.V income_statement (annual, 2021-07-31) — Net Non Operating Interest Income Expense: -13604.00
CONE.V income_statement (annual, 2021-07-31) — Normalized Income: -264258.00
CONE.V income_statement (annual, 2021-07-31) — Other Income Expense: 21208.00
CONE.V cash_flow (annual, 2021-07-31) — Other Non Cash Items: 34812.00
CONE.V income_statement (annual, 2021-07-31) — Other Non Operating Income Expenses: 21208.00
CONE.V income_statement (annual, 2021-07-31) — Other Special Charges: -21208.00
CONE.V income_statement (annual, 2021-07-31) — Salaries And Wages: 0.00
CONE.V income_statement (annual, 2021-07-31) — Write Off: -21208.00
CONE.V income_statement (annual, 2022-07-31) — +Operating Expense: 445988.00
CONE.V income_statement (annual, 2022-07-31) — +Total Revenue: 0.00
CONE.V balance_sheet (annual, 2022-07-31) — Accounts Payable: 489401.00
CONE.V income_statement (annual, 2022-07-31) — Basic Average Shares: 22613456.00
CONE.V income_statement (annual, 2022-07-31) — Basic EPS: -0.01
CONE.V cash_flow (annual, 2022-07-31) — Beginning Cash Position: 6518.00
CONE.V cash_flow (annual, 2022-07-31) — Capital Expenditure: -27343.00
CONE.V cash_flow (annual, 2022-07-31) — Capital Expenditure Reported: -27343.00
CONE.V balance_sheet (annual, 2022-07-31) — Capital Stock: 19923937.00
CONE.V balance_sheet (annual, 2022-07-31) — Cash And Cash Equivalents: 159.00
CONE.V balance_sheet (annual, 2022-07-31) — Cash Cash Equivalents And Short Term Investments: 159.00
CONE.V balance_sheet (annual, 2022-07-31) — Cash Financial: 159.00
CONE.V cash_flow (annual, 2022-07-31) — Cash Flow From Continuing Financing Activities: 130634.00
CONE.V cash_flow (annual, 2022-07-31) — Cash Flow From Continuing Investing Activities: -27343.00
CONE.V cash_flow (annual, 2022-07-31) — Cash Flow From Continuing Operating Activities: -109650.00
CONE.V cash_flow (annual, 2022-07-31) — Change In Account Payable: 283792.00
CONE.V cash_flow (annual, 2022-07-31) — Change In Payable: 327739.00
CONE.V cash_flow (annual, 2022-07-31) — Change In Payables And Accrued Expense: 327739.00
CONE.V cash_flow (annual, 2022-07-31) — Change In Prepaid Assets: 2000.00
CONE.V cash_flow (annual, 2022-07-31) — Change In Receivables: 10598.00
CONE.V cash_flow (annual, 2022-07-31) — Change In Working Capital: 340337.00
CONE.V cash_flow (annual, 2022-07-31) — Changes In Cash: -6359.00
CONE.V balance_sheet (annual, 2022-07-31) — Common Stock: 19923937.00
CONE.V balance_sheet (annual, 2022-07-31) — Common Stock Equity: -1286087.00
CONE.V income_statement (annual, 2022-07-31) — Cost Of Revenue: 20650.00
CONE.V balance_sheet (annual, 2022-07-31) — Current Accrued Expenses: 16000.00
CONE.V balance_sheet (annual, 2022-07-31) — Current Assets: 12742.00
CONE.V balance_sheet (annual, 2022-07-31) — Current Debt: 298809.00
CONE.V balance_sheet (annual, 2022-07-31) — Current Debt And Capital Lease Obligation: 298809.00
CONE.V balance_sheet (annual, 2022-07-31) — Current Liabilities: 1343475.00
CONE.V income_statement (annual, 2022-07-31) — Diluted Average Shares: 22613456.00
CONE.V income_statement (annual, 2022-07-31) — Diluted EPS: -0.01
CONE.V income_statement (annual, 2022-07-31) — Diluted NI Availto Com Stockholders: -310959.00
CONE.V balance_sheet (annual, 2022-07-31) — Dueto Related Parties Current: 555265.00
CONE.V income_statement (annual, 2022-07-31) — EBIT: -306960.00
CONE.V income_statement (annual, 2022-07-31) — EBITDA: -306960.00
CONE.V cash_flow (annual, 2022-07-31) — End Cash Position: 159.00
CONE.V cash_flow (annual, 2022-07-31) — Financing Cash Flow: 130634.00
CONE.V cash_flow (annual, 2022-07-31) — Free Cash Flow: -109650.00
CONE.V income_statement (annual, 2022-07-31) — General And Administrative Expense: 186430.00
CONE.V income_statement (annual, 2022-07-31) — Gross Profit: -20650.00
CONE.V income_statement (annual, 2022-07-31) — Interest Expense: 3999.00
CONE.V income_statement (annual, 2022-07-31) — Interest Expense Non Operating: 3999.00
CONE.V balance_sheet (annual, 2022-07-31) — Invested Capital: -987278.00
CONE.V cash_flow (annual, 2022-07-31) — Investing Cash Flow: -27343.00
CONE.V cash_flow (annual, 2022-07-31) — Issuance Of Debt: 130634.00
CONE.V cash_flow (annual, 2022-07-31) — Long Term Debt Issuance: 130634.00
CONE.V cash_flow (annual, 2022-07-31) — Long Term Debt Payments: 0.00
CONE.V balance_sheet (annual, 2022-07-31) — Net Debt: 298650.00
CONE.V income_statement (annual, 2022-07-31) — Net Income: -310959.00
CONE.V income_statement (annual, 2022-07-31) — Net Income Common Stockholders: -310959.00
CONE.V income_statement (annual, 2022-07-31) — Net Income Continuous Operations: -310959.00
CONE.V income_statement (annual, 2022-07-31) — Net Income From Continuing And Discontinued Operation: -310959.00
CONE.V income_statement (annual, 2022-07-31) — Net Income From Continuing Operation Net Minority Interest: -310959.00
CONE.V cash_flow (annual, 2022-07-31) — Net Income From Continuing Operations: -310959.00
CONE.V income_statement (annual, 2022-07-31) — Net Income Including Noncontrolling Interests: -310959.00
CONE.V income_statement (annual, 2022-07-31) — Net Interest Income: -3999.00
CONE.V cash_flow (annual, 2022-07-31) — Net Issuance Payments Of Debt: 130634.00
CONE.V cash_flow (annual, 2022-07-31) — Net Long Term Debt Issuance: 130634.00
CONE.V income_statement (annual, 2022-07-31) — Net Non Operating Interest Income Expense: -3999.00
CONE.V cash_flow (annual, 2022-07-31) — Net Other Investing Changes: -27343.00
CONE.V balance_sheet (annual, 2022-07-31) — Net PPE: 21646.00
CONE.V balance_sheet (annual, 2022-07-31) — Net Tangible Assets: -1286087.00
CONE.V income_statement (annual, 2022-07-31) — Normalized EBITDA: -306960.00
CONE.V income_statement (annual, 2022-07-31) — Normalized Income: -310959.00
CONE.V cash_flow (annual, 2022-07-31) — Operating Cash Flow: -109650.00
CONE.V income_statement (annual, 2022-07-31) — Operating Income: -445988.00
CONE.V income_statement (annual, 2022-07-31) — Operating Revenue: 0.00
CONE.V balance_sheet (annual, 2022-07-31) — Ordinary Shares Number: 22613456.00
CONE.V balance_sheet (annual, 2022-07-31) — Other Current Borrowings: 298809.00
CONE.V balance_sheet (annual, 2022-07-31) — Other Equity Interest: 2255457.00
CONE.V income_statement (annual, 2022-07-31) — Other Gand A: 165780.00
CONE.V income_statement (annual, 2022-07-31) — Other Income Expense: 139028.00
CONE.V cash_flow (annual, 2022-07-31) — Other Non Cash Items: -139028.00
CONE.V balance_sheet (annual, 2022-07-31) — Other Non Current Assets: 23000.00
CONE.V income_statement (annual, 2022-07-31) — Other Non Operating Income Expenses: 139028.00
CONE.V income_statement (annual, 2022-07-31) — Other Operating Expenses: 194558.00
CONE.V income_statement (annual, 2022-07-31) — Other Special Charges: -139028.00
CONE.V balance_sheet (annual, 2022-07-31) — Payables: 1044666.00
CONE.V balance_sheet (annual, 2022-07-31) — Payables And Accrued Expenses: 1044666.00
CONE.V balance_sheet (annual, 2022-07-31) — Prepaid Assets: 0.00
CONE.V income_statement (annual, 2022-07-31) — Pretax Income: -310959.00
CONE.V balance_sheet (annual, 2022-07-31) — Receivables: 12583.00
CONE.V income_statement (annual, 2022-07-31) — Reconciled Cost Of Revenue: 20650.00
CONE.V income_statement (annual, 2022-07-31) — Rent And Landing Fees: 20650.00
CONE.V income_statement (annual, 2022-07-31) — Rent Expense Supplemental: 20650.00
CONE.V cash_flow (annual, 2022-07-31) — Repayment Of Debt: 0.00
CONE.V balance_sheet (annual, 2022-07-31) — Retained Earnings: -23465481.00
CONE.V income_statement (annual, 2022-07-31) — Selling And Marketing Expense: 65000.00
CONE.V income_statement (annual, 2022-07-31) — Selling General And Administration: 251430.00
CONE.V balance_sheet (annual, 2022-07-31) — Share Issued: 22613456.00
CONE.V income_statement (annual, 2022-07-31) — Special Income Charges: 139028.00
CONE.V balance_sheet (annual, 2022-07-31) — Stockholders Equity: -1286087.00
CONE.V balance_sheet (annual, 2022-07-31) — Tangible Book Value: -1286087.00
CONE.V income_statement (annual, 2022-07-31) — Tax Effect Of Unusual Items: 0.00
CONE.V income_statement (annual, 2022-07-31) — Tax Rate For Calcs: 0.00
CONE.V balance_sheet (annual, 2022-07-31) — Taxes Receivable: 12583.00
CONE.V balance_sheet (annual, 2022-07-31) — Total Assets: 57388.00
CONE.V balance_sheet (annual, 2022-07-31) — Total Capitalization: -1286087.00
CONE.V balance_sheet (annual, 2022-07-31) — Total Debt: 298809.00
CONE.V balance_sheet (annual, 2022-07-31) — Total Equity Gross Minority Interest: -1286087.00
CONE.V income_statement (annual, 2022-07-31) — Total Expenses: 445988.00
CONE.V balance_sheet (annual, 2022-07-31) — Total Liabilities Net Minority Interest: 1343475.00
CONE.V balance_sheet (annual, 2022-07-31) — Total Non Current Assets: 44646.00
CONE.V balance_sheet (annual, 2022-07-31) — Total Non Current Liabilities Net Minority Interest: 0.00
CONE.V income_statement (annual, 2022-07-31) — Total Unusual Items: 139028.00
CONE.V income_statement (annual, 2022-07-31) — Total Unusual Items Excluding Goodwill: 139028.00
CONE.V balance_sheet (annual, 2022-07-31) — Working Capital: -1330733.00
CONE.V income_statement (annual, 2022-07-31) — Write Off: -139028.00
CONE.V income_statement (annual, 2023-07-31) — +Operating Expense: 419460.00
CONE.V income_statement (annual, 2023-07-31) — +Total Revenue: 0.00
CONE.V balance_sheet (annual, 2023-07-31) — Accounts Payable: 547804.00
CONE.V cash_flow (annual, 2023-07-31) — Asset Impairment Charge: 0.00
CONE.V income_statement (annual, 2023-07-31) — Basic Average Shares: 22613456.00
CONE.V income_statement (annual, 2023-07-31) — Basic EPS: -0.02
CONE.V cash_flow (annual, 2023-07-31) — Beginning Cash Position: 159.00
CONE.V cash_flow (annual, 2023-07-31) — Capital Expenditure: -113931.00
CONE.V cash_flow (annual, 2023-07-31) — Capital Expenditure Reported: -113931.00
CONE.V balance_sheet (annual, 2023-07-31) — Capital Stock: 19923937.00
CONE.V balance_sheet (annual, 2023-07-31) — Cash And Cash Equivalents: 125399.00
CONE.V balance_sheet (annual, 2023-07-31) — Cash Cash Equivalents And Short Term Investments: 125399.00
CONE.V balance_sheet (annual, 2023-07-31) — Cash Financial: 125399.00
CONE.V cash_flow (annual, 2023-07-31) — Cash Flow From Continuing Financing Activities: 921197.00
CONE.V cash_flow (annual, 2023-07-31) — Cash Flow From Continuing Investing Activities: -99931.00
CONE.V cash_flow (annual, 2023-07-31) — Cash Flow From Continuing Operating Activities: -696026.00
CONE.V cash_flow (annual, 2023-07-31) — Change In Account Payable: 38585.00
CONE.V cash_flow (annual, 2023-07-31) — Change In Payable: -278515.00
CONE.V cash_flow (annual, 2023-07-31) — Change In Payables And Accrued Expense: -278515.00
CONE.V cash_flow (annual, 2023-07-31) — Change In Prepaid Assets: -5001.00
CONE.V cash_flow (annual, 2023-07-31) — Change In Receivables: 6950.00
CONE.V cash_flow (annual, 2023-07-31) — Change In Working Capital: -276566.00
CONE.V cash_flow (annual, 2023-07-31) — Changes In Cash: 125240.00
CONE.V balance_sheet (annual, 2023-07-31) — Common Stock: 19923937.00
CONE.V balance_sheet (annual, 2023-07-31) — Common Stock Equity: -809214.00
CONE.V cash_flow (annual, 2023-07-31) — Common Stock Issuance: 0.00
CONE.V income_statement (annual, 2023-07-31) — Cost Of Revenue: 31200.00
CONE.V balance_sheet (annual, 2023-07-31) — Current Assets: 136033.00
CONE.V balance_sheet (annual, 2023-07-31) — Current Debt: 323673.00
CONE.V balance_sheet (annual, 2023-07-31) — Current Debt And Capital Lease Obligation: 323673.00
CONE.V balance_sheet (annual, 2023-07-31) — Current Liabilities: 1109642.00
CONE.V income_statement (annual, 2023-07-31) — Diluted Average Shares: 22613456.00
CONE.V income_statement (annual, 2023-07-31) — Diluted EPS: -0.02
CONE.V income_statement (annual, 2023-07-31) — Diluted NI Availto Com Stockholders: -419460.00
CONE.V balance_sheet (annual, 2023-07-31) — Dueto Related Parties Current: 238165.00
CONE.V income_statement (annual, 2023-07-31) — EBIT: -419460.00
CONE.V income_statement (annual, 2023-07-31) — EBITDA: -419460.00
CONE.V cash_flow (annual, 2023-07-31) — End Cash Position: 125399.00
CONE.V cash_flow (annual, 2023-07-31) — Financing Cash Flow: 921197.00
CONE.V cash_flow (annual, 2023-07-31) — Free Cash Flow: -696026.00
CONE.V income_statement (annual, 2023-07-31) — General And Administrative Expense: 142251.00
CONE.V income_statement (annual, 2023-07-31) — Gross Profit: -31200.00
CONE.V income_statement (annual, 2023-07-31) — Impairment Of Capital Assets: 0.00
CONE.V income_statement (annual, 2023-07-31) — Interest Expense: 0.00
CONE.V income_statement (annual, 2023-07-31) — Interest Expense Non Operating: 0.00
CONE.V balance_sheet (annual, 2023-07-31) — Invested Capital: -485541.00
CONE.V cash_flow (annual, 2023-07-31) — Investing Cash Flow: -99931.00
CONE.V cash_flow (annual, 2023-07-31) — Issuance Of Capital Stock: 0.00
CONE.V cash_flow (annual, 2023-07-31) — Issuance Of Debt: 51364.00
CONE.V cash_flow (annual, 2023-07-31) — Long Term Debt Issuance: 51364.00
CONE.V cash_flow (annual, 2023-07-31) — Long Term Debt Payments: -26500.00
CONE.V cash_flow (annual, 2023-07-31) — Net Common Stock Issuance: 0.00
CONE.V balance_sheet (annual, 2023-07-31) — Net Debt: 198274.00
CONE.V income_statement (annual, 2023-07-31) — Net Income: -419460.00
CONE.V income_statement (annual, 2023-07-31) — Net Income Common Stockholders: -419460.00
CONE.V income_statement (annual, 2023-07-31) — Net Income Continuous Operations: -419460.00
CONE.V income_statement (annual, 2023-07-31) — Net Income From Continuing And Discontinued Operation: -419460.00
CONE.V income_statement (annual, 2023-07-31) — Net Income From Continuing Operation Net Minority Interest: -419460.00
CONE.V cash_flow (annual, 2023-07-31) — Net Income From Continuing Operations: -419460.00
CONE.V income_statement (annual, 2023-07-31) — Net Income Including Noncontrolling Interests: -419460.00
CONE.V income_statement (annual, 2023-07-31) — Net Interest Income: 0.00
CONE.V cash_flow (annual, 2023-07-31) — Net Issuance Payments Of Debt: 24864.00
CONE.V cash_flow (annual, 2023-07-31) — Net Long Term Debt Issuance: 51364.00
CONE.V income_statement (annual, 2023-07-31) — Net Non Operating Interest Income Expense: 0.00
CONE.V cash_flow (annual, 2023-07-31) — Net Other Financing Charges: 896333.00
CONE.V cash_flow (annual, 2023-07-31) — Net Other Investing Changes: -99931.00
CONE.V balance_sheet (annual, 2023-07-31) — Net PPE: 155395.00
CONE.V cash_flow (annual, 2023-07-31) — Net PPE Purchase And Sale: 0.00
CONE.V cash_flow (annual, 2023-07-31) — Net Short Term Debt Issuance: -26500.00
CONE.V balance_sheet (annual, 2023-07-31) — Net Tangible Assets: -809214.00
CONE.V income_statement (annual, 2023-07-31) — Normalized EBITDA: -419460.00
CONE.V income_statement (annual, 2023-07-31) — Normalized Income: -419460.00
CONE.V cash_flow (annual, 2023-07-31) — Operating Cash Flow: -696026.00
CONE.V income_statement (annual, 2023-07-31) — Operating Income: -419460.00
CONE.V income_statement (annual, 2023-07-31) — Operating Revenue: 0.00
CONE.V balance_sheet (annual, 2023-07-31) — Ordinary Shares Number: 22613456.00
CONE.V balance_sheet (annual, 2023-07-31) — Other Current Borrowings: 323673.00
CONE.V balance_sheet (annual, 2023-07-31) — Other Equity Interest: 3151790.00
CONE.V income_statement (annual, 2023-07-31) — Other Gand A: 111051.00
CONE.V balance_sheet (annual, 2023-07-31) — Other Non Current Assets: 9000.00
CONE.V income_statement (annual, 2023-07-31) — Other Operating Expenses: 227660.00
CONE.V balance_sheet (annual, 2023-07-31) — Payables: 785969.00
CONE.V balance_sheet (annual, 2023-07-31) — Payables And Accrued Expenses: 785969.00
CONE.V balance_sheet (annual, 2023-07-31) — Prepaid Assets: 5001.00
CONE.V income_statement (annual, 2023-07-31) — Pretax Income: -419460.00
CONE.V cash_flow (annual, 2023-07-31) — Purchase Of PPE: 0.00
CONE.V balance_sheet (annual, 2023-07-31) — Receivables: 5633.00
CONE.V income_statement (annual, 2023-07-31) — Reconciled Cost Of Revenue: 31200.00
CONE.V income_statement (annual, 2023-07-31) — Rent And Landing Fees: 31200.00
CONE.V income_statement (annual, 2023-07-31) — Rent Expense Supplemental: 31200.00
CONE.V cash_flow (annual, 2023-07-31) — Repayment Of Debt: -26500.00
CONE.V balance_sheet (annual, 2023-07-31) — Retained Earnings: -23884941.00
CONE.V income_statement (annual, 2023-07-31) — Selling And Marketing Expense: 49549.00
CONE.V income_statement (annual, 2023-07-31) — Selling General And Administration: 191800.00
CONE.V balance_sheet (annual, 2023-07-31) — Share Issued: 22613456.00
CONE.V cash_flow (annual, 2023-07-31) — Short Term Debt Payments: -26500.00
CONE.V income_statement (annual, 2023-07-31) — Special Income Charges: 0.00
CONE.V balance_sheet (annual, 2023-07-31) — Stockholders Equity: -809214.00
CONE.V balance_sheet (annual, 2023-07-31) — Tangible Book Value: -809214.00
CONE.V income_statement (annual, 2023-07-31) — Tax Effect Of Unusual Items: 0.00
CONE.V income_statement (annual, 2023-07-31) — Tax Rate For Calcs: 0.00
CONE.V balance_sheet (annual, 2023-07-31) — Taxes Receivable: 5633.00
CONE.V balance_sheet (annual, 2023-07-31) — Total Assets: 300428.00
CONE.V balance_sheet (annual, 2023-07-31) — Total Capitalization: -809214.00
CONE.V balance_sheet (annual, 2023-07-31) — Total Debt: 323673.00
CONE.V balance_sheet (annual, 2023-07-31) — Total Equity Gross Minority Interest: -809214.00
CONE.V income_statement (annual, 2023-07-31) — Total Expenses: 419460.00
CONE.V balance_sheet (annual, 2023-07-31) — Total Liabilities Net Minority Interest: 1109642.00
CONE.V balance_sheet (annual, 2023-07-31) — Total Non Current Assets: 164395.00
CONE.V balance_sheet (annual, 2023-07-31) — Total Non Current Liabilities Net Minority Interest: 0.00
CONE.V income_statement (annual, 2023-07-31) — Total Unusual Items: 0.00
CONE.V income_statement (annual, 2023-07-31) — Total Unusual Items Excluding Goodwill: 0.00
CONE.V balance_sheet (annual, 2023-07-31) — Working Capital: -973609.00
CONE.V income_statement (annual, 2024-07-31) — +Operating Expense: 775023.00
CONE.V income_statement (annual, 2024-07-31) — +Total Revenue: 0.00
CONE.V balance_sheet (annual, 2024-07-31) — Accounts Payable: 801391.00
CONE.V cash_flow (annual, 2024-07-31) — Asset Impairment Charge: 81668.00
CONE.V income_statement (annual, 2024-07-31) — Basic Average Shares: 40695147.00
CONE.V income_statement (annual, 2024-07-31) — Basic EPS: -0.02
CONE.V cash_flow (annual, 2024-07-31) — Beginning Cash Position: 125399.00
CONE.V cash_flow (annual, 2024-07-31) — Capital Expenditure: -7570.00
CONE.V balance_sheet (annual, 2024-07-31) — Capital Stock: 21505019.00
CONE.V balance_sheet (annual, 2024-07-31) — Cash And Cash Equivalents: 5159.00
CONE.V balance_sheet (annual, 2024-07-31) — Cash Cash Equivalents And Short Term Investments: 5159.00
CONE.V balance_sheet (annual, 2024-07-31) — Cash Financial: 5159.00
CONE.V cash_flow (annual, 2024-07-31) — Cash Flow From Continuing Financing Activities: 163250.00
CONE.V cash_flow (annual, 2024-07-31) — Cash Flow From Continuing Investing Activities: 165042.00
CONE.V cash_flow (annual, 2024-07-31) — Cash Flow From Continuing Operating Activities: -448532.00
CONE.V cash_flow (annual, 2024-07-31) — Change In Account Payable: 211065.00
CONE.V cash_flow (annual, 2024-07-31) — Change In Payable: 365212.00
CONE.V cash_flow (annual, 2024-07-31) — Change In Payables And Accrued Expense: 365212.00
CONE.V cash_flow (annual, 2024-07-31) — Change In Prepaid Assets: -42349.00
CONE.V cash_flow (annual, 2024-07-31) — Change In Receivables: 1258.00
CONE.V cash_flow (annual, 2024-07-31) — Change In Working Capital: 324121.00
CONE.V cash_flow (annual, 2024-07-31) — Changes In Cash: -120240.00
CONE.V balance_sheet (annual, 2024-07-31) — Common Stock: 21505019.00
CONE.V balance_sheet (annual, 2024-07-31) — Common Stock Equity: -835655.00
CONE.V cash_flow (annual, 2024-07-31) — Common Stock Issuance: 125000.00
CONE.V income_statement (annual, 2024-07-31) — Cost Of Revenue: 48000.00
CONE.V balance_sheet (annual, 2024-07-31) — Current Assets: 56884.00
CONE.V balance_sheet (annual, 2024-07-31) — Current Debt: 335173.00
CONE.V balance_sheet (annual, 2024-07-31) — Current Debt And Capital Lease Obligation: 335173.00
CONE.V balance_sheet (annual, 2024-07-31) — Current Liabilities: 1528876.00
CONE.V income_statement (annual, 2024-07-31) — Diluted Average Shares: 40695147.00
CONE.V income_statement (annual, 2024-07-31) — Diluted EPS: -0.02
CONE.V income_statement (annual, 2024-07-31) — Diluted NI Availto Com Stockholders: -856691.00
CONE.V balance_sheet (annual, 2024-07-31) — Dueto Related Parties Current: 392312.00
CONE.V income_statement (annual, 2024-07-31) — EBIT: -775023.00
CONE.V income_statement (annual, 2024-07-31) — EBITDA: -775023.00
CONE.V cash_flow (annual, 2024-07-31) — End Cash Position: 5159.00
CONE.V cash_flow (annual, 2024-07-31) — Financing Cash Flow: 163250.00
CONE.V cash_flow (annual, 2024-07-31) — Free Cash Flow: -456102.00
CONE.V income_statement (annual, 2024-07-31) — General And Administrative Expense: 165146.00
CONE.V income_statement (annual, 2024-07-31) — Gross Profit: -48000.00
CONE.V income_statement (annual, 2024-07-31) — Impairment Of Capital Assets: 81668.00
CONE.V balance_sheet (annual, 2024-07-31) — Invested Capital: -500482.00
CONE.V cash_flow (annual, 2024-07-31) — Investing Cash Flow: 165042.00
CONE.V cash_flow (annual, 2024-07-31) — Issuance Of Capital Stock: 125000.00
CONE.V cash_flow (annual, 2024-07-31) — Issuance Of Debt: 35000.00
CONE.V cash_flow (annual, 2024-07-31) — Long Term Debt Issuance: 35000.00
CONE.V cash_flow (annual, 2024-07-31) — Net Common Stock Issuance: 125000.00
CONE.V balance_sheet (annual, 2024-07-31) — Net Debt: 330014.00
CONE.V income_statement (annual, 2024-07-31) — Net Income: -856691.00
CONE.V income_statement (annual, 2024-07-31) — Net Income Common Stockholders: -856691.00
CONE.V income_statement (annual, 2024-07-31) — Net Income Continuous Operations: -856691.00
CONE.V income_statement (annual, 2024-07-31) — Net Income From Continuing And Discontinued Operation: -856691.00
CONE.V income_statement (annual, 2024-07-31) — Net Income From Continuing Operation Net Minority Interest: -856691.00
CONE.V cash_flow (annual, 2024-07-31) — Net Income From Continuing Operations: -856691.00